

# Hendrik Van Poppel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5964954/publications.pdf>

Version: 2024-02-01

161  
papers

9,159  
citations

57758

44  
h-index

42399

92  
g-index

238  
all docs

238  
docs citations

238  
times ranked

8343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	5.4	4
2	Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>Eur Urol</i> 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?. <i>European Urology</i> , 2022, 81, e23-e24.	1.9	0
3	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 527-541.	3.4	3
4	Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. <i>European Urology Focus</i> , 2022, 8, 1187-1191.	3.1	3
5	Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients. <i>European Urology Focus</i> , 2021, 7, 987-994.	3.1	23
6	Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. <i>European Urology Focus</i> , 2021, 7, 574-581.	3.1	30
7	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. <i>World Journal of Urology</i> , 2021, 39, 399-406.	2.2	4
8	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 267-282.	2.4	3
9	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	5.4	2
10	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	3.7	13
11	Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 3177-3185.	2.2	7
12	Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>European Urology</i> , 2021, 79, 327-329.	1.9	54
13	C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 239.e17-239.e25.	1.6	13
14	Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 7.e9-7.e17.	1.6	0
15	Reply to Laura Evangelista and Egesta Lopci's Letter to the Editor re: Hendrik Van Poppel, RenA@e Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327-329: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy. <i>European Urology</i> , 2021, 80, e23-e24.	1.9	0
16	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	1.9	9
17	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021, 60, 1499-1506.	1.8	12
18	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>European Urology</i> , 2021, 80, 703-711.	1.9	108

#	ARTICLE	IF	CITATIONS
19	A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 731-739.	5.4	51
20	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	3.8	38
21	Nuclear medicine theranostics comes of age. <i>Lancet Oncology</i> , The, 2021, 22, 1497-1498.	10.7	11
22	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. <i>European Urology Oncology</i> , 2020, 3, 209-215.	5.4	37
23	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
24	Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 830-837.	1.0	19
25	Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. <i>Cancers</i> , 2020, 12, 2271.	3.7	18
26	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 493-499.	1.0	12
27	Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 937.e1-937.e9.	1.6	5
28	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	1.9	239
29	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020, 17, 351-362.	3.8	18
30	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	1.9	74
31	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	1.9	16
32	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large multi-institutional cohort. <i>BJU International</i> , 2020, 126, 704-714.	2.5	7
33	European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. <i>European Urology</i> , 2020, 77, 397-399.	1.9	1
34	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.4	32
35	The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. <i>PLoS ONE</i> , 2020, 15, e0244663.	2.5	11
36	Metastasectomy of oligometastatic urothelial cancer: a single-center experience. <i>Translational Andrology and Urology</i> , 2020, 9, 1296-1305.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. <i>Translational Andrology and Urology</i> , 2020, 9, 2541-2554.	1.4	15
38	Prognostic score predicts overall survival following complete urinary tract extirpation. <i>Scandinavian Journal of Urology</i> , 2020, 54, 70-79.	1.0	2
39	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.4	0
40	Uro-oncology in the era of social distancing: the principles of patient-centered online consultations during the COVID-19 pandemic. <i>Central European Journal of Urology</i> , 2020, 73, 260-264.	0.3	2
41	Title is missing!. , 2020, 15, e0244663.		0
42	Title is missing!. , 2020, 15, e0244663.		0
43	Title is missing!. , 2020, 15, e0244663.		0
44	Title is missing!. , 2020, 15, e0244663.		0
45	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	5.4	19
46	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	1.9	151
47	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 781.	2.8	7
48	Open and robotic radical prostatectomy. <i>Asian Journal of Urology</i> , 2019, 6, 125-128.	1.2	11
49	Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. <i>World Journal of Urology</i> , 2019, 37, 1507-1515.	2.2	16
50	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	1.9	48
51	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 142-150.	1.9	80
52	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1543-1549.	2.2	19
53	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	1.9	15
54	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	1.9	14

#	ARTICLE	IF	CITATIONS
55	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 141-149.	5.4	73
56	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. <i>European Urology Oncology</i> , 2019, 2, 365-378.	5.4	47
57	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	1.9	8
58	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 1857-1866.	2.2	23
59	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , 2019, 75, 176-183.	1.9	101
60	Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. <i>Eur Urol</i> 2018;74:84-91. <i>European Urology</i> , 2019, 75, e23-e24.	1.9	0
61	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , 2018, 74, 474-480.	1.9	72
62	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 84-91.	1.9	136
63	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	1.9	13
64	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>European Urology Focus</i> , 2018, 4, 369-375.	3.1	17
65	Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. <i>European Urology</i> , 2018, 73, 290-300.	1.9	128
66	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e605-e612.	1.9	37
67	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	1.9	60
68	Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018, 1, 512-523.	5.4	30
69	Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores. <i>Scientific Reports</i> , 2018, 8, 14326.	3.3	4
70	Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages â‰¥ cT1b: a single institution, matched analysis. <i>Central European Journal of Urology</i> , 2018, 71, 48-57.	0.3	3
71	Harnessing New Media Tools in Patient Information. <i>European Urology</i> , 2018, 74, 685-687.	1.9	2
72	The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. <i>Minerva Urology and Nephrology</i> , 2018, 70, 109-125.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 357-368.	1.9	105
74	Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? In Favour. <i>European Oncology and Haematology</i> , 2018, 14, 12.	0.0	0
75	Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. <i>BJU International</i> , 2017, 120, E52-E58.	2.5	6
76	Changing Current Practice in Urology: Improving Guideline Development and Implementation Through Stakeholder Engagement. <i>European Urology</i> , 2017, 72, 161-163.	1.9	13
77	Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. <i>European Urology</i> , 2017, 71, 811-819.	1.9	23
78	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. <i>European Urology</i> , 2017, 72, 64-75.	1.9	91
79	Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy. <i>European Urology Focus</i> , 2017, 3, 599-605.	3.1	12
80	Identifying critical steps towards improved access to innovation in cancer care: a European Cancer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	2.8	25
81	International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 97.	2.4	18
82	Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , 2017, 77, 3-9.	2.3	8
83	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017, 71, 886-893.	1.9	77
84	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	1.9	11
85	Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. <i>Biomedicine Hub</i> , 2017, 2, 1-7.	1.2	1
86	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 280.	2.8	9
87	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. <i>SpringerPlus</i> , 2016, 5, 646.	1.2	10
88	Nephron Sparing for Renal Cell Carcinoma: Whenever Possible?. <i>European Urology Focus</i> , 2016, 2, 656-659.	3.1	9
89	Renal Preservation and Partial Nephrectomy: Patient and Surgical Factors. <i>European Urology Focus</i> , 2016, 2, 589-600.	3.1	71
90	Evans blue-mediated white-light detection of non-muscle-invasive bladder cancer: A preclinical feasibility and safety study using a rat bladder urothelial cell carcinoma model. <i>Molecular and Clinical Oncology</i> , 2016, 5, 678-688.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Staging of prostatic carcinoma at 1.5-T MRI: correlation of a simplified MRI exam with whole-mount radical prostatectomy specimens. <i>British Journal of Radiology</i> , 2016, 89, 20160101.	2.2	5
92	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 333-340.	0.8	16
93	Evaluation of conservative approach in the management of ureteroenteric strictures following radical cystectomy with Bricker ileal conduit: a single-center experience. <i>Scandinavian Journal of Urology</i> , 2016, 50, 439-444.	1.0	7
94	The Role of Cytoréductive Nephrectomy: European Association of Urology Recommendations in 2016. <i>European Urology</i> , 2016, 70, 901-905.	1.9	36
95	Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLadder cancer Trial. <i>European Journal of Cancer</i> , 2016, 69, 9-18.	2.8	17
96	Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 13-22.	4.4	30
97	Parenchymal Volumetric Assessment as a Predictive Tool to Determine Renal Function Benefit of Nephron-Sparing Surgery Compared with Radical Nephrectomy. <i>Journal of Endourology</i> , 2016, 30, 114-121.	2.1	32
98	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 234.e13-234.e19.	1.6	15
99	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 728-733.	1.9	102
100	Biodistribution of Evans blue in an orthotopic AY rat bladder urothelial cell carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer (NMIBC) using dye-guided white-light cystoscopy. <i>BJU International</i> , 2015, 116, 468-477.	2.5	11
101	Clinically relevant genetic characterization of prostate tumors: How close are we to the goal?. <i>Korean Journal of Urology</i> , 2015, 56, 90.	1.2	1
102	Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts. <i>BJU International</i> , 2015, 116, 93-101.	2.5	123
103	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. <i>European Urology</i> , 2015, 67, 646-648.	1.9	25
104	Natural history of surgically treated high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 163.e7-163.e13.	1.6	101
105	Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. <i>European Urology</i> , 2015, 68, 61-74.	1.9	274
106	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	4.4	23
107	Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1277-1284.	0.4	65
108	Current status and effectiveness of mentorship programmes in urology: a systematic review. <i>BJU International</i> , 2015, 116, 487-494.	2.5	12

#	ARTICLE	IF	CITATIONS
109	Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. <i>European Urology</i> , 2015, 67, 157-164.	1.9	180
110	Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. <i>European Urology</i> , 2015, 67, 319-325.	1.9	14
111	Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9522-32.	0.5	10
112	Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?. <i>Asian Journal of Urology</i> , 2014, 1, 40-45.	1.2	11
113	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , 2014, 21, T105-T118.	3.1	116
114	The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making. <i>BioMed Research International</i> , 2014, 2014, 1-16.	1.9	35
115	EAU Policy on Live Surgery Events. <i>European Urology</i> , 2014, 66, 87-97.	1.9	50
116	Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities. <i>European Journal of Cancer</i> , 2014, 50, 1957-1963.	2.8	4
117	Early Salvage Radiotherapy Following Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1034-1043.	1.9	171
118	Renal Function After Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904. <i>European Urology</i> , 2014, 65, 372-377.	1.9	448
119	Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 655-663.	1.9	16
120	Re: The Role of Surgery in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2014, 66, 387-389.	1.9	0
121	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2014, 66, 479-486.	1.9	121
122	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 960-967.	0.8	16
123	Tumour-related imaging parameters predicting the percentage of preserved normal renal parenchyma following nephron sparing surgery: a retrospective study. <i>European Radiology</i> , 2013, 23, 280-286.	4.5	11
124	Expression of a Distinct Set of Chemokine Receptors in Adipose Tissue-Derived Stem Cells is Responsible for In Vitro Migration Toward Chemokines Appearing in the Major Pelvic Ganglion Following Cavernous Nerve Injury. <i>Sexual Medicine</i> , 2013, 1, 3-15.	1.6	24
125	Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5001-5001.	1.6	13
126	Open partial nephrectomy for complex tumours and >4 cm: Is it still the gold standard technique in the minimally invasive era?. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 129-38.	0.2	3



#	ARTICLE	IF	CITATIONS
127	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet</i> , The, 2012, 380, 2018-2027.	13.7	759
128	Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. <i>BMC Urology</i> , 2012, 12, 8.	1.4	18
129	Gonadotropin-releasing hormone: An update review of the antagonists versus agonists. <i>International Journal of Urology</i> , 2012, 19, 594-601.	1.0	88
130	Positive Surgical Margins After Nephron-Sparing Surgery. <i>European Urology</i> , 2012, 61, 757-763.	1.9	186
131	A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 543-552.	1.9	910
132	Treatment of Localised Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 662-672.	1.9	198
133	Cardiovascular risk during hormonal treatment in patients with prostate cancer. <i>Cancer Management and Research</i> , 2011, 3, 49.	1.9	14
134	Chemoprevention of prostate cancer with nutrients and supplements. <i>Cancer Management and Research</i> , 2011, 3, 91.	1.9	20
135	Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. <i>European Urology</i> , 2010, 57, 466-473.	1.9	225
136	Efficacy and safety of nephron-sparing surgery. <i>International Journal of Urology</i> , 2010, 17, 314-326.	1.0	61
137	Evaluation of degarelix in the management of prostate cancer. <i>Cancer Management and Research</i> , 2010, 2, 39.	1.9	25
138	Vaccine Therapy in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 1333-1344.	1.9	62
139	Prepubic urethrectomy. <i>BJU International</i> , 2009, 103, 118-132.	2.5	6
140	Radical Prostatectomy for Locally Advanced Prostate Cancer. , 2009, , 281-288.		0
141	An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate Cancer. <i>European Urology</i> , 2008, 53, 253-259.	1.9	101
142	Re: Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate Cancer. <i>European Urology</i> , 2008, 54, 1440-1441.	1.9	0
143	Is nephron-sparing surgery as safe and effective as radical nephrectomy in patients with locally advanced RCC?. <i>Nature Reviews Urology</i> , 2008, 5, 296-297.	1.4	1
144	Should the pT2 tumor classification for renal cell carcinoma be subdivided according to tumor size?. <i>Nature Reviews Urology</i> , 2007, 4, 648-649.	1.4	1

#	ARTICLE	IF	CITATIONS
145	A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. <i>European Urology</i> , 2007, 51, 1606-1615.	1.9	572
146	Editorial Comment on: Tamoxifen as Prophylaxis for Prevention of Gynaecomastia and Breast Pain Associated with Bicalutamide 150mg Monotherapy in Patients with Prostate Cancer: A Randomised, Placebo-Controlled, Dose-Response Study. <i>European Urology</i> , 2007, 52, 115.	1.9	7
147	Is Surveillance an Option for the Treatment of Small Renal Masses?. <i>European Urology</i> , 2007, 52, 1323-1330.	1.9	57
148	Radical cystectomy with or without urethrectomy?. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 141-145.	4.4	26
149	Treatment of Erectile Dysfunction by Perineal Exercise, Electromyographic Biofeedback, and Electrical Stimulation. <i>Physical Therapy</i> , 2003, 83, 536-543.	2.4	56
150	Precancerous Lesions in the Kidney. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 136-165.	1.4	20
151	BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP. <i>Journal of Urology</i> , 2000, 164, 1579-1582.	0.4	310
152	Involvement of 12q12-13 is a nonrandom chromosome change in renal oncocytoma. , 1999, 24, 94-94.		7
153	PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA CAN ACHIEVE LONG-TERM TUMOR CONTROL. <i>Journal of Urology</i> , 1998, 160, 674-678.	0.4	141
154	Microscopic Vascular Invasion is the Most Relevant Prognosticator After Radical Nephrectomy for Clinically Nonmetastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 1997, 158, 45-49.	0.4	137
155	The t(1; 12)(p36;q13) in a Renal Oncocytoma. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 136-139.	2.8	13
156	Benign Angiomyolipoma Involving the Renal Vein and Vena Cava as a Tumor Thrombus: Case Report. <i>Journal of Urology</i> , 1995, 153, 1205-1207.	0.4	36
157	Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer: Interim Results of a Prospective Randomized Trial. <i>Journal of Urology</i> , 1995, 154, 429-434.	0.4	152
158	Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer. <i>Journal of Urology</i> , 1995, 154, 429-434.	0.4	74
159	Chromosome abnormalities in benign prostatic hyperplasia. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 227-233.	2.8	31
160	The Percutaneous Operative Gastrostomy for Gastric Decompression in Major Urological Surgery. <i>Journal of Urology</i> , 1991, 145, 100-102.	0.4	5
161	Prepubic Urethrectomy. <i>Journal of Urology</i> , 1989, 142, 1536-1537.	0.4	16